CEO的透视治疗公司购买了更多的股份,显示出对癌症试验进展的信心。 CEO of Perspective Therapeutics buys more shares, showing confidence in cancer trial progress.

一家开发有针对性的癌症疗法的生物技术公司,即“透视治疗公司”,其首席执行官Johan M. Spoor购买了22 026股股份,将持有的股份提高到59 383股。 Perspective Therapeutics Inc., a biotech firm developing targeted cancer therapies, saw its CEO Johan M. Spoor purchase 22,026 shares, raising his holding to 59,383 shares. 股票购买表明他对公司第1/2阶段临床试验进展的信心。 The stock purchase underscores his confidence in the company's Phase 1/2a clinical trial progress. 该公司的股票目前交易额为1.96美元,协商一致的目标价格为14.44美元,分析师的平均“Buy”评级为“Buy”。 The firm's stock, currently trading at $1.96, has a consensus target price of $14.44 and an average "Buy" rating from analysts.